ASH 2020 | Comparing transplant outcomes in acute leukemia

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the results of a number of retrospective analyses of transplant outcomes for patients with acute leukemia in the European Society for Blood and Marrow Transplantation registry. Firstly, an analysis comparing transplantation outcomes between haploidentical allogeneic hematopoietic stem cell transplantation (allo-HCT) and matched sibling donor transplants (MSD) in over 2300 patients with acute lymphoblastic leukemia (ALL) was conducted. Overall, the survival outcomes of adult patients with ALL in complete remission receiving allo-HCT from haploidentical donors was found not to be significantly different from those receiving transplants from MSD. Prof. Nagler also discusses a comparison of autologous HCT and reduced intensity conditioning-allo-HCT in ALL, which gave promising data supporting the use of auto-HCT as an alternative option for these patients, and a study of cord blood transplant versus singe antigen-mismatched unrelated donor allo-HCT in acute myeloid leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.